Cardiology | Home | MIMS Malaysia

Malaysia
Search
Sign In

Cardiology Search

Cardiology

Cardiology

Home News Diseases Conferences Special Reports Multimedia

Curcumin supplementation confers no additional benefit for CV risk factors in NAFLD

3 hours ago

Taking curcumin daily in addition to losing weight does not exert a superior effect on cardiovascular (CV) risk factors in patients with nonalcoholic fatty liver disease (NAFLD) when compared with losing weight alone, according to a study.

Endogenous testosterone tied to thromboembolism, heart failure, MI in men

Stephen Padilla, Yesterday

Endogenous testosterone appears to play a significant role in thromboembolism, heart failure (HF) and myocardial infarction (MI), with rates of these conditions higher in men than women, according to a recent study. Existing treatment can control endogenous testosterone, which can be a modifiable risk factor for HF and thromboembolism.

Implanted vascular access devices safe for cancer patients

Tristan Manalac, Yesterday

In cancer patients given BioFlo implanted vascular access devices (IVADs), IVAD-related upper extremity deep vein thrombosis (UEDVT) appears to be an uncommon complication, according to a new study.

Dapagliflozin provides robust benefits in T2DM patients with prior MI, HF or PAD

Dr. Joseph Delano Fule Robles, Yesterday

Treatment with the sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin benefits patients with type 2 diabetes mellitus (T2DM) with prior MI, heart failure with reduced ejection fraction (HFrEF) or peripheral arterial disease (PAD), according to results of subanalyses of the DECLARE-TIMI 58 trial presented at the American College of Cardiology’s 68^th Annual Scientific Session.

Real-world management of stable coronary artery disease

Dr. Choo Gim Hooi, Assoc Prof. Pattarapong Makarawate, Dr. Krisada Sastravaha, 17 Dec 2018

Coronary artery disease (CAD) is a leading cause of mortality and morbidity globally and its burden is expected to increase due to the rising prevalence of risk factors such as hypertension, diabetes, and dyslipidaemia. In conjunction with the 23rd ASEAN Federation of Cardiology Congress held in Bangkok, Thailand, Menarini organized a lunch symposium and product theatre to discuss the significance of optimal medical therapy (OMT) in the management of stable CAD, with a focus on the role of ranolazine (Ranexa^®).

Defining trends and patterns of cardiovascular risk in Asia: The LIFECARE study

30 Nov 2018

Despite risk factors for cardiovascular disease (CVD) being similar around the world, the burden of CVD is not uniform across nations. Furthermore, CVD-related death in low- to middle-income countries (LMICs) has increased by two-thirds in the last 30 years, and now account for a whopping 80% of global deaths due to CVD.

Tailored strategies to overcome statin non-adherence

30 Nov 2018

Poor adherence to statin therapy is leaving many patients with dyslipidaemia at high risk of potentially life-threatening cardiovascular events. Statins are the current standard of care for reducing the risk of cardiovascular disease in these patients and for improving life expectancy, with possible economic benefits for healthcare systems too. However, many patients with dyslipidaemia are not achieving or maintaining treatment targets because they fail to stick to their prescribed statin therapy. An article co-authored by lipidologist Peter Lansberg, and published in Vascular Health and Risk Management, considers this issue and reviews approaches to overcome non-adherence.

Fenofibrate linked with reduced CV risk and DR progression, but how?

28 Nov 2018

At the Abbott-sponsored symposium held during the 9th Malaysian Endocrine and Metabolic Society Annual Congres sat Hilton Kuala Lumpur, Dr Zanariah Hussein shared her insights into the important role of an emerging marker of hypercholesterolaemia, and its relationship with cardiovascular (CV) and diabetic retinopathy (DR) risks.

Secondary prevention: Best practices in reducing ASCVD burden in Malaysia

27 Nov 2018

Through a cardiology webcast co-hosted by Pfizer, the National Heart Association of Malaysia (NHAM), and the American College of Cardiology (ACC), Dr Ong Mei Lin, Dr Aaron D. Kugelmass and Dr Tracy Wang shared their insights into the importance of secondary prevention measures in reducing the burden of atherosclerotic cardiovascular disease (ASCVD).

Improving glycaemic outcomes and providing cardiovascular protection in patients with T2DM

21 Nov 2018

At the AstraZeneca-sponsored symposium held during the 9th Malaysian Endocrine and Metabolic Society Annual Congress at Hilton Kuala Lumpur, Professor Ronald Ma highlighted the role of a novel combination therapy in reducing HbA1c levels while simultaneously providing cardiovascular (CV) protection to improve patient outcomes.

Optimizing CV outcomes with evolocumab

Dr. Robert Giugliano, Prof. Ulrich Laufs, Prof. Gaetano De Ferrari, Prof. Naveed Sattar, 11 Oct 2018

The FOURIER trial previously demonstrated that adding the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab to background statin therapy lowered LDL-cholesterol (LDL-C) below target levels and significantly reduced the risks of cardiovascular (CV) events in patients with atherosclerotic cardiovascular disease (ASCVD). At the European Society of Cardiology (ESC) Congress 2018 in Munich, Germany, experts reiterated how evolocumab helps lower LDL-C levels and reduces CV events even in patients with various comorbidities.

Dapagliflozin provides robust benefits in T2DM patients with prior MI, HF or PAD

Dr. Joseph Delano Fule Robles, 19 Mar 2019

Glucose control within 12 hours of stroke onset: How low can you go?

Elvira Manzano, 04 Mar 2019

The perception that the more aggressive glucose control is the better the patient will be doesn’t hold true in the multicentre SHINE* trial. Intensive glucose control at a target of 80–130 mg/dL with intravenous (IV) insulin did not improve outcomes in patients with ischaemic stroke. Instead, it carried an increased risk of severe hypoglycaemia.

Breast cancer survivors have increasing stroke risk with survivorship

Elaine Soliven, 26 Feb 2019

Breast cancer survivors saw increasing risk of stroke along with growing duration of survivorship, particularly during the post-menopausal period, according to a study presented at ISC 2019.

Intensive/guideline-directed BP-lowering after ischaemic stroke yield similar functional outcomes

Roshini Claire Anthony, 25 Feb 2019

Among patients with a recent acute ischaemic stroke treated with thrombolytic therapy, intensive blood pressure (BP)-lowering conferred no additional benefit in functional recovery compared with guideline-recommended BP-lowering, despite a reduced risk of intracranial haemorrhage with intensive therapy, according to results of the ENCHANTED* trial.

Stroke dovetails with spikes in opioid misuse, infective endocarditis

Elvira Manzano, 25 Feb 2019

Hospitalization rates for stroke increased by 20 percent each year between 2008 and 2015, according to a large US study, and these incidents were apparently tied to spikes in opioid misuse and cases of drug-related infective endocarditis.

New study EXTENDs tPA window to 9 hours in select stroke patients

Pearl Toh, 21 Feb 2019

Patients presenting within 9 hours from stroke onset or with wake-up stroke can still benefit from thrombolytic therapy based on automated computed tomography (CT) perfusion imaging-guided patient selection, according to the EXTEND* study presented at ISC 2019.

Hydrogel coil trumps standard coil for aneurysm recurrence

Pearl Toh, 19 Feb 2019

Treatment with the second-generation hydrogel coils significantly reduces the rate of aneurysm recurrence compared with standard platinum coils, with no increase in adverse events, reveals the HEAT* study presented at ISC 2019.

Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!